Floatz logo

TAMOXIFEN

Ductal Carcinoma

Dana-Farber Cancer InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Ductal Carcinoma cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Dana-Farber Cancer Institute
Phase 2CCC
Docetaxel
Sanofi
Phase 2CCC
Inno-206
Sanofi
Phase 2CCC
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2CCC
Htert
University of Pennsylvania
Phase 1CC

View all 10 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →